• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Bioresorbable Scaffolds: Is There Still Light at the End of the Tunnel?

作者信息

Serruys Patrick W, Revaiah Pruthvi C, Onuma Yoshinobu

机构信息

CORRIB Research Centre for Advanced Imaging and Core Laboratory, University of Galway, Galway, Ireland.

CORRIB Research Centre for Advanced Imaging and Core Laboratory, University of Galway, Galway, Ireland.

出版信息

J Am Coll Cardiol. 2023 Jul 18;82(3):196-199. doi: 10.1016/j.jacc.2023.05.023.

DOI:10.1016/j.jacc.2023.05.023
PMID:37438005
Abstract
摘要

相似文献

1
Bioresorbable Scaffolds: Is There Still Light at the End of the Tunnel?生物可吸收支架：隧道尽头是否仍有曙光？
J Am Coll Cardiol. 2023 Jul 18;82(3):196-199. doi: 10.1016/j.jacc.2023.05.023.
2
A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial.生物可吸收依维莫司洗脱支架与金属依维莫司洗脱支架治疗初发原生冠状动脉病变所致缺血性心脏病的比较（ABSORB II）：一项随机对照临床试验的临床和操作次要终点 1 年中期分析。
Lancet. 2015 Jan 3;385(9962):43-54. doi: 10.1016/S0140-6736(14)61455-0. Epub 2014 Sep 14.
3
Economic Outcomes of Bioresorbable Vascular Scaffolds Versus Everolimus-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention: 1-Year Results From the ABSORB III Trial.经皮冠状动脉介入治疗患者中生物可吸收血管支架与依维莫司洗脱支架的经济学结局：ABSORB III 试验 1 年结果。
JACC Cardiovasc Interv. 2017 Apr 24;10(8):774-782. doi: 10.1016/j.jcin.2017.01.022.
4
Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a meta-analysis of randomised controlled trials.依维莫司洗脱生物可吸收血管支架与依维莫司洗脱金属支架的比较：随机对照试验的荟萃分析。
Lancet. 2016 Feb 6;387(10018):537-544. doi: 10.1016/S0140-6736(15)00979-4. Epub 2015 Nov 17.
5
Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial.对比依维莫司洗脱生物可吸收支架与依维莫司洗脱金属支架治疗冠状动脉狭窄的疗效（ABSORB II）：3 年随机、对照、单盲、多中心临床试验。
Lancet. 2016 Nov 19;388(10059):2479-2491. doi: 10.1016/S0140-6736(16)32050-5. Epub 2016 Oct 30.
6
Bioresorbable Scaffolds for Coronary Artery Disease.用于冠状动脉疾病的生物可吸收支架
Curr Cardiol Rep. 2017 Jan;19(1):5. doi: 10.1007/s11886-017-0812-7.
7
Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease.依维莫司洗脱生物可吸收支架治疗冠状动脉疾病。
N Engl J Med. 2015 Nov 12;373(20):1905-15. doi: 10.1056/NEJMoa1509038. Epub 2015 Oct 12.
8
Bioresorbable scaffolds for the treatment of coronary artery disease: current status and future perspective.用于治疗冠状动脉疾病的生物可吸收支架：现状与未来展望。
Expert Rev Med Devices. 2014 Sep;11(5):467-80. doi: 10.1586/17434440.2014.941812. Epub 2014 Aug 2.
9
Bioresorbable Scaffolds versus Metallic Stents in Routine PCI.生物可吸收支架与金属支架在常规 PCI 中的应用比较。
N Engl J Med. 2017 Jun 15;376(24):2319-2328. doi: 10.1056/NEJMoa1614954. Epub 2017 Mar 29.
10
The Impact of Post-Procedural Asymmetry, Expansion, and Eccentricity of Bioresorbable Everolimus-Eluting Scaffold and Metallic Everolimus-Eluting Stent on Clinical Outcomes in the ABSORB II Trial.在 ABSORB II 试验中，生物可吸收依维莫司洗脱支架和金属依维莫司洗脱支架的术后对称性、扩张和偏心对临床结果的影响。
JACC Cardiovasc Interv. 2016 Jun 27;9(12):1231-1242. doi: 10.1016/j.jcin.2016.03.027. Epub 2016 Jun 1.

引用本文的文献

1
Progress in research and development of biodegradable metallic vascular stents.可生物降解金属血管支架的研发进展
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2024 Nov 28;49(11):1861-1868. doi: 10.11817/j.issn.1672-7347.2024.230514.
2
A new resorbable magnesium scaffold (DREAMS 3G): 12-month vasomotion results from the BIOMAG-I first-in-human study.一种新型可吸收镁支架（DREAMS 3G）：BIOMAG-I首次人体研究的12个月血管运动结果
EuroIntervention. 2024 Sep 2;20(17):e1118-e1120. doi: 10.4244/EIJ-D-24-00355.
3
Identification of endothelial protein C receptor as a novel druggable agonistic target for reendothelialization promotion and thrombosis prevention of eluting stent.
鉴定内皮细胞蛋白C受体为促进洗脱支架再内皮化和预防血栓形成的新型可成药激动靶点。
Bioact Mater. 2024 Aug 9;41:485-498. doi: 10.1016/j.bioactmat.2024.07.028. eCollection 2024 Nov.